Deferiprone

Generic Name: Deferiprone

Brand Names: Ferriprox, Deferiprone Lipomed

Drug Type: Small Molecule

Chemical Formula: C_₇H_₉NO_₂

CAS Number: 30652-11-0

Unique Ingredient Identifier: 2BTY8KH53L

Background: Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011.

Indication: Deferiprone is indicated in thalassemia syndromes when first line chelation agents are not adequate to treat transfusional iron overload.

Associated Conditions: Transfusional Iron Overload

Associated Therapies: -

Clinical Trials

Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis

Phase 2

Active, not recruiting

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Placebo Oral Tablet
Drug: Deferiprone

First Posted Date: 2017-09-26

Last Posted Date: 2022-11-07

Lead Sponsor: University Hospital, Lille

Target Recruit Count: 372

Registration Number: NCT03293069

Locations: 🇫🇷
Aphm Hopital La Timone, Marseille, France
🇫🇷
Chr Angers, Angers, France
🇫🇷
Chu de Nancy, Nancy, France

and more 12 locations

Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy

Phase 2

Conditions: Diabetes Mellitus
Gastroduodenal Ulcer
Sensorineural Hearing Loss
Platelet Dysfunction
Iron Metabolism Disorders
Optic Atrophy

Interventions: Drug: Deferiprone
Drug: Acetylcysteine
Drug: Sitagliptin and Metformin

First Posted Date: 2016-08-29

Last Posted Date: 2016-08-29

Lead Sponsor: Hadassah Medical Organization

Target Recruit Count: 20

Registration Number: NCT02882477

Locations: 🇮🇱
Hadassah medical center, Jerusalem, Israel

Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes

Not Applicable

Completed

Conditions: Oxidative Stress
Iron Overload
Parkinson's Disease
Amyotrophic Lateral Sclerosis

Interventions: Drug: deferiprone
Drug: placebo

First Posted Date: 2016-08-26

Last Posted Date: 2020-03-27

Lead Sponsor: University Hospital, Lille

Target Recruit Count: 90

Registration Number: NCT02880033

Locations: 🇫🇷
Hôpital Roger Salengro, CHRU de Lille, Lille, France

A Pilot of the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment

Early Phase 1

Withdrawn

Conditions: Mild Cognitive Impairment

Interventions: Other: Placebo phase
Drug: Deferiprone

First Posted Date: 2016-08-25

Last Posted Date: 2018-02-06

Lead Sponsor: The University of Texas Health Science Center at San Antonio

Registration Number: NCT02878538

Locations: 🇺🇸
University of Texas Health Science Center, San Antonio, Texas, United States

Study of Parkinson's Early Stage With Deferiprone

Phase 2

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Placebo
Drug: Deferiprone

First Posted Date: 2016-04-05

Last Posted Date: 2024-04-10

Lead Sponsor: ApoPharma

Target Recruit Count: 140

Registration Number: NCT02728843

Locations: 🇫🇷
CHU Charles Nicoll - Rouen, Rouen, France
🇬🇧
Newcastle Clinical Ageing Research Unit, Newcastle Upon Tyne, United Kingdom
🇩🇪
UKSH Campus Kiel, Neurologie, Kiel, Germany

and more 17 locations

Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease

Phase 2

Completed

Conditions: Parkinson Disease

Interventions: Drug: Placebo
Drug: Deferiprone

First Posted Date: 2016-01-14

Last Posted Date: 2022-11-07

Lead Sponsor: University Hospital, Lille

Target Recruit Count: 372

Registration Number: NCT02655315

Locations: 🇵🇹
Centro Hospitalar e universitario de Coimbra, Coimbra, Portugal
🇫🇷
Hôpital Wertheimer, Bron, France
🇦🇹
Medizinische Universitat Innsbruck, Innsbruck, Austria

and more 22 locations

Compassionate Use of Deferiprone in Patients With PKAN

Conditions: Pantothenate Kinase-Associated Neurodegeneration

First Posted Date: 2015-12-21

Last Posted Date: 2022-11-14

Lead Sponsor: Chiesi Canada Corp

Registration Number: NCT02635841

Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients

Phase 2

Completed

Conditions: Myelodysplastic Syndrome With Low-grade Lesions
Iron Overload Due to Repeated Red Blood Cell Transfusions

Interventions: Drug: Deferiprone

First Posted Date: 2015-06-23

Last Posted Date: 2018-11-01

Lead Sponsor: Sheba Medical Center

Target Recruit Count: 19

Registration Number: NCT02477631

Locations: 🇮🇱
Chim Sheba Medical Center, Tel Hashomer, Israel

Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias

Phase 4

Terminated

Conditions: Iron Overload
Sickle Cell Disease
Other Anemias

Interventions: Drug: Deferiprone

First Posted Date: 2015-05-14

Last Posted Date: 2024-01-10

Lead Sponsor: ApoPharma

Target Recruit Count: 134

Registration Number: NCT02443545

Locations: 🇪🇬
Zagazig University, Alexandria, Egypt
🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇨🇦
Hospital for Sick Kids, Toronto, Ontario, Canada

and more 10 locations

Antiretroviral Activity and Pharmacokinetics of Deferiprone in Healthy Volunteers and Asymptomatic HIV-infected Subjects

Phase 1

Completed

Conditions: HIV Infection

Interventions: Drug: Deferiprone

First Posted Date: 2014-07-16

Last Posted Date: 2014-07-16

Lead Sponsor: ApoPharma

Target Recruit Count: 26

Registration Number: NCT02191657

Locations: 🇿🇦
PAREXEL International, Bloemfontein,, South Africa

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy